CART

Oncology

Move over CAR-T: The potential of NK cells in cell therapy

The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th

News

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressi

Partner Content

Precision era products and services are blurred_16_9

Partner Content

Move over CAR-T: The potential of NK cells in cell therapy

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

In the precision medicine era, the line between products and...

Ipsen charts $1.75bn course for Kartos acquisition

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks